Risk stratification of childhood medulloblastoma in the molecular era: the current consensusVijay Ramaswamy, Scott L. Pomeroy, Stefan M. Pfister et al.|Acta Neuropathologica|2016Cited by 650
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Christophe Le Tourneau, Martin Schüler et al.|The Lancet Oncology|2023Cited by 195
The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic AstrocytomaJuliane L. Buhl, Till Milde, Florian Selt et al.|Clinical Cancer Research|2018Cited by 84
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaCornelis M. van Tilburg, Olaf Witt, Till Milde et al.|Clinical Epigenetics|2019Cited by 44
Histone deacetylase inhibitor <i>Helminthosporium carbonum</i> (HC)‐toxin suppresses the malignant phenotype of neuroblastoma cellsHedwig E. Deubzer, Olaf Witt|International Journal of Cancer|2007Cited by 41